{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=7", "query": { "condition": "Phase 1", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 18599, "total_pages": 1860, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T05:35:03.903Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04741542", "title": "Safety of SP-420 in the Treatment of Transfusional Iron Overload", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Iron Overload" ], "interventions": [ { "name": "SP-420", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-03-09", "completion_date": "2024-01-10", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04741542" }, { "nct_id": "NCT00477542", "title": "A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 18, "start_date": "2007-05", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2014-09-18", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477542" }, { "nct_id": "NCT00024986", "title": "Tenofovir Disoproxil Fumarate to Treat Pediatric HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Tenofovir DF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2001-10", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024986" }, { "nct_id": "NCT03317405", "title": "Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma In Situ", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ", "Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Endoxifen Hydrochloride", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2018-10-31", "completion_date": "2027-08-12", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 3, "location_summary": "Los Angeles, California • Chicago, Illinois • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317405" }, { "nct_id": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "Enoblituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 25, "start_date": "2016-12", "completion_date": "2019-05-22", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 6, "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982941" }, { "nct_id": "NCT04262466", "title": "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Select Advanced Solid Tumors" ], "interventions": [ { "name": "Brenetafusp", "type": "DRUG" }, { "name": "Brenetafusp and pembrolizumab", "type": "DRUG" }, { "name": "Brenetafusp and chemotherapy", "type": "DRUG" }, { "name": "Brenetafusp and monoclonal antibodies and chemotherapy", "type": "DRUG" }, { "name": "Brenetafusp and tebentafusp", "type": "DRUG" }, { "name": "Brenetafusp and bevacizumab", "type": "DRUG" }, { "name": "Brenetafusp and kinase inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2020-02-25", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262466" }, { "nct_id": "NCT02567656", "title": "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Peripheral", "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "RP6530", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhizen Pharmaceuticals SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2015-09", "completion_date": "2018-12-10", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 8, "location_summary": "Duarte, California • Orange, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567656" }, { "nct_id": "NCT04629729", "title": "FT819 in Subjects With B-cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell", "Chronic Lymphocytic Leukemia", "Precursor B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "FT819", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-07-12", "completion_date": "2039-09-30", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629729" }, { "nct_id": "NCT00361803", "title": "Topotecan Pharmacokinetic Characterization Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2006-09-12", "completion_date": "2007-08-09", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361803" }, { "nct_id": "NCT03674827", "title": "Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "PF-06936308", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-11-27", "completion_date": "2021-09-27", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-23T05:35:03.903Z", "location_count": 34, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674827" } ] }